Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Business & Industry
- Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
- Bayer transforms pharma business through breakthrough innovation in healthcare
- Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
- An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
- European Commission authorizes COVID-19 vaccine Moderna in Europe
Research & Development
- New England Journal of Medicine publishes COVID-19 treatment trial results
- Scientists identify 'immune cop' that detects SARS-CoV-2
- New findings help explain how COVID-19 overpowers the immune system
- New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
- Sustained cellular immune dysregulation in individuals recovering from COVID-19
- How SARS-CoV-2 interacts with cells
- Neutralizing antibodies protect against severe COVID-19
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
- FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2